INOVIO PHARMACEUTICALS, INC. (INO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
INO currently has 82.3M outstanding shares. with significant dilution risk as 50.1M authorized shares could dilute existing holders by 60.9%. The company has significantly diluted shareholders by 137.08% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 82.3M shares outstanding |
82M | 50M |
| Mar 12, 2026 |
10-K filing | 69.1M shares outstanding |
69M | 50M |
| May 13, 2025 |
10-Q filing | 38.6M shares outstanding |
39M | 50M |
| Mar 18, 2025 |
10-K filing | 36.7M shares outstanding |
37M | 50M |
| Nov 14, 2024 |
10-Q filing | 28.1M shares outstanding |
28M | 50M |
| Aug 08, 2024 |
10-Q filing | 27.2M shares outstanding |
27M | 50M |
| May 13, 2024 |
10-Q filing | 25.9M shares outstanding |
26M | 50M |
| Mar 06, 2024 |
10-K filing | 22.2M shares outstanding |
22M | 50M |
| Jan 26, 2024 |
S-3/A filing: This S-3/A filing from Inovio Pharmaceuticals, Inc. registers debt securities, common stock, preferred stock, warrants, and unallocated shelf offerings. |
260M | 50M |
| Nov 09, 2023 |
10-Q filing | 268.6M shares outstanding |
270M | 50M |
| Nov 09, 2023 |
S-3 filing: The company intends to offer and sell up to $300,000,000 of any combination of common stock, preferred stock and debt securities from time to time. |
260M | 50M |
| Aug 09, 2023 |
10-Q filing | 264.4M shares outstanding |
260M | 50M |
| May 10, 2023 |
10-Q filing | 258.4M shares outstanding |
260M | 50M |
| Mar 01, 2023 |
POS AM filing: The filing is a POS AM for an at-the-market offering of common stock with a proposed amount of $300,000,000. |
250M | 50M |
| Mar 01, 2023 |
10-K filing | 238.6M shares outstanding |
240M | 50M |
| Nov 08, 2022 |
10-Q filing | 249.4M shares outstanding |
250M | 50M |
| Aug 09, 2022 |
10-Q filing | 235.3M shares outstanding |
240M | 50M |
| May 10, 2022 |
10-Q filing | 218.9M shares outstanding |
220M | 50M |
| Mar 01, 2022 |
10-K filing | 208.8M shares outstanding |
210M | 50M |
| Nov 09, 2021 |
10-Q filing | 210.3M shares outstanding |
210M | 50M |
| Aug 09, 2021 |
10-Q filing | 209.6M shares outstanding |
210M | 50M |
| May 10, 2021 |
10-Q filing | 209.4M shares outstanding |
210M | 50M |
| Mar 01, 2021 |
10-K filing | 207.6M shares outstanding |
210M | 50M |
| Nov 09, 2020 |
10-Q filing | 165.4M shares outstanding |
170M | 50M |
| Aug 10, 2020 |
10-Q filing | 167.5M shares outstanding |
170M | 50M |
| May 11, 2020 |
10-Q filing | 158.1M shares outstanding |
160M | 50M |
| Mar 13, 2020 |
S-3 filing: The filing is an S-3 registration statement for a shelf offering of up to $400,000,000 of common stock, preferred stock, and/or debt securities. |
150M | 50M |
| Mar 12, 2020 |
10-K filing | 145.8M shares outstanding |
150M | 8M |
| Jan 31, 2020 |
S-3 filing: This S-3 filing registers the resale of up to 8,014,201 shares of common stock issuable upon conversion of convertible bonds sold to selling stockholders. |
N/A | 8M |